Welcome Alexander Markov as our VP & CMO at Biokinetica GmbH in the USA

9 September 2021

We are very pleased to welcome Alexander Markov, MD, PhD as our new VP and CMO at Biokinetica GmbH in the USA.

Dr Alexander Markov brings more than 23 years of experience in the pharmaceutical industry to Biokinetica Early Phase Institute. He joins with a wealth of knowledge and experience in medical affairs, clinical operations, pharmacovigilance, regulatory affairs, and quality assurance. Alexander was responsible for the Clinical Operations team, which for many years successfully managed multiple global clinical trials in respiratory, allergy, oncology, urology, cardiology, and vaccines areas. His expertise will be a great asset in supporting our efforts as a valued Early Phase clinical service and consultancy provider.

Dr Markov holds PhD and DSc degrees in Allergy and Clinical Immunology. After completing his studies, he spent several years in Canada and the US as an assistant professor and research fellow to eventually start his career at GSK as the Medical and Regulatory Affairs Director supporting the Eastern European Market. Subsequently, Alexander served in several roles of progressively increasing seniority, including Area Medical and Quality Assurance Director for CIS countries. Soon Dr Markov completes 6 years as the Medical Director of Ukraine and CIS countries at Takeda.

We are honored to have Alexander on board helping us expand our presence on the US market and strengthen our position as a boutique Early Phase company for early clinical trials with healthy volunteers and patients.